glp 1 meds covered by insurance Costly GLP-1 Drugs are Rarely for Weight Loss Marketplace Plans GLP-1 insurance change impacts millions

Deprince A, Haas JT, Staels B

Targeting the PGD 2/CRTH2/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives

A second cohort of 209,649 patients with both IBD and T2D, of whom 38,567 had received a GLP-1 RA, was matched similarly, yielding 37,740 patients for analysis

Of these trials, four compared DPP-4 inhibitors against placebo (SAVOR-TIMI 53, EXAMINE, TECOS, CARMELINA), eight compared GLP-1RA against placebo (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER 6, AMPLITUTE-O) and eleven compared SGLT-2 inhibitors against placebo (EMPA-REG, CANVAS, DECLARE, CREDENCE, DAPA-HF, DAPA CKD, VERTIS-CV, EMPEROR-R, SCORED, SOLOIST-WHF, EMPEROR-P)

These numbers are staggering because obesity is strongly associated with several conditions such as heart disease, stroke, type 2 diabetes, and cancer